Literature DB >> 30216221

Microsatellite Instability (MSI) as an Independent Predictor of Pathologic Complete Response (PCR) in Locally Advanced Rectal Cancer: A National Cancer Database (NCDB) Analysis.

Shaakir Hasan1, Paul Renz1, Rodney E Wegner1, Gene Finley2, Moses Raj2, Dulabh Monga2, James McCormick3, Alexander Kirichenko1.   

Abstract

OBJECTIVE: The relationship between microsatellite instability (MSI) and response to neoadjuvant chemoradiation in rectal cancer is not well understood.
BACKGROUND: We utilized the National Cancer Database (NCDB) to investigate the association between MSI and pathologic complete response (pCR) in this patient population.
METHODS: We analyzed 5086 patients between 2010 and 2015 with locally advanced rectal cancer who were tested for MSI and treated definitively with chemoradiation followed by surgery. Primary comparison groups were between 4450 MSI-negative(-) and 636 MSI-positive(+) patients. Multivariable regression analysis was conducted to identify demographic, therapeutic, and clinical characteristics predictive of pCR. Cox proportional-hazard ratios were used for survival.
RESULTS: All patients were treated with definitive chemoradiation (median dose 50.4 Gy) followed by resection within 4 months. MSI(+) patients were associated with earlier year of diagnosis and higher-grade tumors (P < 0.05).The overall pCR rate was 8.6%, including 8.9% for MSI(-) and 5.9% for MSI(+) tumors (P = 0.01). Along with lower T stage, MSI(+) cases were significantly associated with a reduced pCR rate (odds ratio 0.65, 95% confidence interval 0.43-0.96) with multivariable analysis. The 5-year survival for patients with pCR was 93% compared with 73% without it (<0.001).
CONCLUSION: Microsatellite instability was independently associated with a reduction in pCR for locally advanced rectal cancer after neoadjuvant chemoradiation in this NCDB-based analysis.

Entities:  

Mesh:

Year:  2020        PMID: 30216221      PMCID: PMC7418064          DOI: 10.1097/SLA.0000000000003051

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  30 in total

Review 1.  Genetics of rectal cancer and novel therapies: primer for radiologists.

Authors:  Sebastian Mondaca; Rona Yaeger
Journal:  Abdom Radiol (NY)       Date:  2019-11

2.  Microsatellite Instability Correlated Inflammatory Markers and their Prognostic Value in the Rectal Cancer Following Neoadjuvant Chemoradiotherapy: A Hypothesis-generating Study.

Authors:  Joo Ho Lee; Byung-Hee Kang; Changhoon Song; Sung-Bum Kang; Hye Seung Lee; Keun-Wook Lee; Eui Kyu Chie; Jae-Sung Kim
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

Review 3.  Potential risks associated with the use of ionizing radiation for imaging and treatment of colorectal cancer in Lynch syndrome patients.

Authors:  Mingzhu Sun; Jayne Moquet; Michele Ellender; Simon Bouffler; Christophe Badie; Rachel Baldwin-Cleland; Kevin Monahan; Andrew Latchford; David Lloyd; Susan Clark; Nicola A Anyamene; Elizabeth Ainsbury; David Burling
Journal:  Fam Cancer       Date:  2022-06-20       Impact factor: 2.375

4.  Predicting Neoadjuvant Treatment Response in Rectal Cancer Using Machine Learning: Evaluation of MRI-Based Radiomic and Clinical Models.

Authors:  Kent J Peterson; Matthew T Simpson; Melissa K Drezdzon; Aniko Szabo; Robin A Ausman; Andrew S Nencka; Paul M Knechtges; Carrie Y Peterson; Kirk A Ludwig; Timothy J Ridolfi
Journal:  J Gastrointest Surg       Date:  2022-10-21       Impact factor: 3.267

5.  Association of mismatch repair status with survival and response to neoadjuvant chemo(radio)therapy in rectal cancer.

Authors:  Shu-Biao Ye; Yi-Kan Cheng; Lin Zhang; Yi-Feng Zou; Ping Chen; Yan-Hong Deng; Yan Huang; Jian-Hong Peng; Xiao-Jian Wu; Ping Lan
Journal:  NPJ Precis Oncol       Date:  2020-09-07

6.  Prognostic Significance of Clinicopathological and Molecular Features After Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients.

Authors:  Hee Jeong Cho; Jin Ho Baek; Dong Won Baek; Byung Woog Kang; Soo Jung Lee; Hye Jin Kim; Su Yeon Park; Jun Seok Park; Gyu Seog Choi; Jong Gwang Kim
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

7.  Proton beam therapy versus stereotactic body radiotherapy for hepatocellular carcinoma: practice patterns, outcomes, and the effect of biologically effective dose escalation.

Authors:  Shaakir Hasan; Stephen Abel; Vivek Verma; Patrick Webster; W Tristam Arscott; Rodney E Wegner; Alexander Kirichenko; Charles B Simone
Journal:  J Gastrointest Oncol       Date:  2019-10

8.  Long-term outcomes by response to neoadjuvant chemotherapy or chemoradiation in patients with resected pancreatic adenocarcinoma.

Authors:  Ahmed Khattab; Sunita Patruni; Stephen Abel; Shaakir Hasan; Ethan B Ludmir; Gene Finley; Dulabh Monga; Rodney E Wegner; Vivek Verma
Journal:  J Gastrointest Oncol       Date:  2019-10

Review 9.  Immunity, immunotherapy, and rectal cancer: A clinical and translational science review.

Authors:  Ebunoluwa E Otegbeye; Jonathan B Mitchem; Haeseong Park; Aadel A Chaudhuri; Hyun Kim; Matthew G Mutch; Matthew A Ciorba
Journal:  Transl Res       Date:  2020-12-08       Impact factor: 7.012

10.  Predictors of chemotherapy and its effects in early stage squamous cell carcinoma of the larynx.

Authors:  Thejus T Jayakrishnan; Richard J White; Larisa Greenberg; Athanasios Colonias; Rodney E Wegner
Journal:  Laryngoscope Investig Otolaryngol       Date:  2019-12-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.